Literature DB >> 22316507

Contrast-induced nephropathy and nephrogenic systemic fibrosis: minimizing the risk.

Boncher A Nicholas1, Gino J Vricella, Michael Smith, Matthew Passalacqua, Vikas Gulani, Lee E Ponsky.   

Abstract

INTRODUCTION: Contrast-enhanced cross-sectional imaging is essential to the urologist's practice. Traditionally, patients with impaired renal function could not be imaged with a computed tomography (CT) scan with contrast due to the risk of contrast-induced nephropathy (CIN). These patients could alternatively be imaged by magnetic resonance imaging (MRI) with gadolinium. However, the recent identification of the association between nephrogenic systemic fibrosis (NSF) and gadolinium administration has created significant challenges for urologists and radiologists when faced with the need for evaluation with contrast-enhanced cross-sectional imaging. In this review, we summarize the most comprehensive articles discussing both NSF and CIN and present a straightforward, evidence-based algorithm to determine the appropriate approach to cross-sectional imaging for all patients, as well as future directions regarding cross-sectional imaging.
MATERIALS AND METHODS: A MEDLINE literature search for review articles from 1966 to August 2009 was performed. Selected additional articles for specific topics were also reviewed. This search yielded a total of 25 articles for NSF and 28 for CIN that were reviewed.
RESULTS: The pathophysiology and risk factors of NSF and CIN are discussed, as well as potential interventions to decrease either morbidity or incidence. A multidisciplinary (urologist, nephrologist, radiologist) evidence-based algorithm is introduced for managing patients in need of cross-sectional imaging.
CONCLUSIONS: The associated risks of contrast-enhanced, cross-sectional imaging has created significant challenges for urologic evaluation. We propose an evidence-based approach to guide patient therapy, which can minimize patient risk and physician anxiety, while simplifying the decision-making process.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22316507

Source DB:  PubMed          Journal:  Can J Urol        ISSN: 1195-9479            Impact factor:   1.344


  6 in total

1.  Diffusion-weighted MRI for Unenhanced Breast Cancer Screening.

Authors:  Nita Amornsiripanitch; Sebastian Bickelhaupt; Hee Jung Shin; Madeline Dang; Habib Rahbar; Katja Pinker; Savannah C Partridge
Journal:  Radiology       Date:  2019-10-08       Impact factor: 11.105

2.  Acute Respiratory Distress Syndrome after the Use of Gadolinium Contrast Media.

Authors:  Jihye Park; Il Hwan Byun; Kyung Hee Park; Jae-Hyun Lee; Eun Ji Nam; Jung-Won Park
Journal:  Yonsei Med J       Date:  2015-07       Impact factor: 2.759

3.  Late-onset acute respiratory distress syndrome induced by a gadolinium-based contrast agent.

Authors:  Kazuhiko Kato; Shota Fujimoto; Shun Inukai; Hiroki Takatsu; Yu Kono; Kenji Kasai
Journal:  Respir Med Case Rep       Date:  2019-12-26

4.  Delayed anaphylaxis due to gadolinium- A rare clinical scenario.

Authors:  Sudeep Acharya; Shamsuddin Anwar; Samragnyi Madala; Sakura Thapa; Rabih Maroun
Journal:  Radiol Case Rep       Date:  2021-07-03

5.  Addition of T2-guided optical tomography improves noncontrast breast magnetic resonance imaging diagnosis.

Authors:  Jinchao Feng; Junqing Xu; Shudong Jiang; Hong Yin; Yan Zhao; Jiang Gui; Ke Wang; Xiuhua Lv; Fang Ren; Brian W Pogue; Keith D Paulsen
Journal:  Breast Cancer Res       Date:  2017-10-24       Impact factor: 6.466

6.  Acute respiratory distress syndrome after the use of gadolinium contrast agent.

Authors:  Bugra Kerget; Alperen Aksakal; Dursun Erol Afşin; Omer Araz; Elif Yılmazel Ucar; Metin Akgün; Leyla Sağlam
Journal:  Respir Med Case Rep       Date:  2018-10-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.